NCT07263932

Brief Summary

Total hip arthroplasty (THA) is a commonly performed surgical procedure, and its incidence continues to rise with the aging population. Effective postoperative analgesia facilitates early mobilization and accelerates recovery. The pericapsular nerve group (PENG) block provides analgesia to the anterior hip capsule by targeting the articular branches of the femoral, obturator, and accessory obturator nerves. However, due to the contribution of sacral plexus-derived nerves (quadratus femoris, superior gluteal, and inferior gluteal nerves) to posterior hip pain, anterior blocks alone may be insufficient. This prospective study aims to compare the efficacy of preoperatively administered PENG block alone versus the combination of PENG and posterior hip pericapsular block (PHPB) in postoperative pain control after total hip arthroplasty. The primary outcome is postoperative pain intensity assessed by the Numerical Rating Scale (NRS). Secondary outcomes include the Quality of Recovery score (QoR-15), opioid consumption, manual muscle testing (MMT) results, time to mobilization, and block-related complications.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
127

participants targeted

Target at P50-P75 for all trials

Timeline
2mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Dec 2025Jul 2026

First Submitted

Initial submission to the registry

November 24, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 4, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

May 6, 2026

Status Verified

October 1, 2025

Enrollment Period

5 months

First QC Date

November 24, 2025

Last Update Submit

May 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative pain

    Postoperative pain will be assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at rest and during movement at 0, 2, 6, 8, 12, 24, 36, and 48 hours after surgery. The NRS scores will be compared between the two study groups (PENG vs. PENG + PHPB) to evaluate the effectiveness of the blocks in postoperative analgesia following total hip arthroplasty.

    Up to 48 hours postoperatively

Secondary Outcomes (5)

  • QUALİTY OF RECOVERY-15

    Preoperative, 24, and 48 hours postoperatively

  • MANUEL MUSCLE TEST

    6, 12, and 24 hours postoperatively

  • Rescue analgesic

    0-48 hours postoperatively

  • Postoperative Nausea and Vomiting (PONV)

    0-48 hours postoperatively

  • Length of Hospital Stay

    Up to discharge (approximately 3-5 days postoperatively)

Study Arms (2)

PENG Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block

Procedure: PENG Block

PENG + PHPB Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block and Posterior Hip Pericapsular Block (PHPB)

Procedure: PENG Block and Posterior Hip Pericapsular Block

Interventions

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule. In addition to the PENG block, a Posterior Hip Pericapsular Block (PHPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The local anesthetic will be injected between the piriformis muscle and the ischiofemoral ligament to target the posterior articular branches of the quadratus femoris, superior gluteal, and inferior gluteal nerves. The combined PENG + PHPB approach aims to provide comprehensive analgesia of both the anterior and posterior hip capsule while preserving motor function.

PENG + PHPB Group
PENG BlockPROCEDURE

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule.

PENG Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients aged 18 years and older, classified as ASA physical status I-II, scheduled for elective total hip arthroplasty under spinal anesthesia at Ankara Bilkent City Hospital. A total of 132 patients who meet the inclusion criteria and provide written informed consent will be enrolled in this single-center, prospective, randomized controlled trial.

You may qualify if:

  • Patients scheduled for elective total hip arthroplasty (THA) under spinal anesthesia
  • ASA physical status I-II
  • Age ≥18 years
  • Body Mass Index (BMI) between 18-35 kg/m²
  • Patients who provide written informed consent

You may not qualify if:

  • Age \<18 years
  • ASA physical status ≥III
  • Known allergy or contraindication to study medications (local anesthetics, opioids, etc.)
  • Severe cardiac, renal, hepatic, or pulmonary failure
  • Revision total hip arthroplasty
  • Coagulopathy or anticoagulant use
  • Local infection or neuropathic findings at the injection site
  • Chronic inflammatory diseases or chronic corticosteroid use
  • Diagnosed neuropsychiatric disorders
  • Pregnancy or lactation
  • Inability or unwillingness to read, understand, or sign the informed consent form
  • Obesity (BMI \>35 kg/m²)
  • Failed spinal anesthesia or conversion to general anesthesia
  • Active malignancy or patients receiving radiotherapy/chemotherapy
  • Active systemic infection or ongoing antibiotic therapy (except prophylaxis)
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation, Ankara,Çankaya

Ankara, Çankaya, 06800, Turkey (Türkiye)

Location

Related Publications (3)

  • Atalay YO, Ciftci B, Tekin B, Ansen G, Sakul BU, Cacan MA, Azboy I, Yilmaz B, Alici HA. A Case Series of Deep Subgluteal Block: A New Block Targeting the Missed Portion of the Hip for Analgesia After Total Hip Replacement. A A Pract. 2024 Sep 9;18(9):e01848. doi: 10.1213/XAA.0000000000001848. eCollection 2024 Sep 1.

  • Duan L, Li J, Chen Z, Wen T, He J, Zhang A. Posterior Hip Pericapsular Block (PHPB) with pericapsular nerve group (PENG) block for hip fracture: a case series. BMC Anesthesiol. 2024 Oct 1;24(1):352. doi: 10.1186/s12871-024-02731-2.

  • Vermeylen K, Van Aken D, Versyck B, Casaer S, Bleys R, Bracke P, Groen G. Deep posterior gluteal compartment block for regional anaesthesia of the posterior hip: a proof-of-concept pilot study. BJA Open. 2023 Feb 15;5:100127. doi: 10.1016/j.bjao.2023.100127. eCollection 2023 Mar.

Study Officials

  • Abdulkadir But, Professor

    Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation,Ankara,Çankaya

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
2 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2025

First Posted

December 4, 2025

Study Start

December 1, 2025

Primary Completion

April 15, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

May 6, 2026

Record last verified: 2025-10

Locations